TrialHaematologica2018

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Marek Trnĕný et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.